semaglutide and hypotension High Blood Pressure: Effects and Management GLP-1s Linked to Low Blood

Total sleep may drop from 7-8 hours to 5.5-6.5 hours

An October 2023 JAMA research letter found gastroparesis risk three to four times higher and pancreatitis risk about nine times higher among GLP-1 users compared to people on Contrave (bupropion-naltrexone)

In contrast, people in the throes of a heart attack are more likely to say they feel chest discomfort rather than pain or tenderness

Tirzepatide SURMOUNT-1 (2022) and SURPASS-2 (2021) SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 non-diabetic adults with BMI 30, 72 weeks of tirzepatide 15 mg/week: Weight loss: 20.9% (vs 3.1% placebo) 91% of participants 5% loss, 56.7% 20% SURPASS-2 (Fras et al., NEJM 2021): 1,879 T2D patients head-to-head vs semaglutide 1 mg: HbA1c: 2.30% (tirzepatide 15 mg) vs 1.86% (semaglutide) Weight loss: 11.2 kg vs 5.7 kg Tirzepatide statistically outperforms semaglutide on both HbA1c and weight in a head-to-head trial a rare outcome in incretin pharmacology